Rapporto
Pharmacy Outlook: Fall 2026 Edition
Powered by Accelerate Pharmacy Solutions, the Pharmacy Outlook: Fall 2026 Edition features insights from 111 health system pharmacy leaders on the forces reshaping pharmacy strategy and performance. The report examines specialty pharmacy, 340B, infusion, cell and gene therapy, technology adoption, and financial sustainability through the lens of real-world health system operations. Readers will gain a clearer understanding of emerging market trends, investment priorities, and evolving leadership perspectives across the industry. Designed for pharmacy and health system executives, the report provides data-driven insights to support strategic planning and informed decision-making.
A few findings from this year’s research
- Prescriptions filled through your health system pharmacy start therapy in 3.2 days on average, compared with 6.7 days when routed externally.
- Home infusion adoption rose from 29% to 40% in a single year, and financial barriers now outrank clinical ones at every site of care.
- Prior authorization support is in place at 90% of health systems, yet payer approval requirements (74%) remain the single largest driver of therapy delay.
- Only 7% of pharmacy teams can evaluate and adopt AI-enabled tools independently, and in most capability areas fewer than half of established implementations use AI at all.
What the report covers
- Specialty pharmacy retention and time to therapy
- 340B strategy as rebate models and claims-data requirements take shape
- Infusion services and site of care
- Cell and gene therapy program economics
- Financial performance, payer pressure, and policy
- AI adoption and pharmacy technology
- Workforce readiness
About Accelerate Pharmacy Solutions
Accelerate Pharmacy Solutions partners with health systems to strengthen pharmacy performance across specialty, 340B, infusion, cell and gene therapy, procurement, and supply chain. The Pharmacy Outlook Report is part of our commitment to advancing health system pharmacy through data-driven insight.
